Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as in contrast with imatinib, for the main-line procedure of CML-CP. 5 hundred and nineteen individuals with newly diagnosed CML-CP were randomly assigned to receive dasatinib at a dose of 100 mg as soon as every day (259 individuals) https://dantedozku.estate-blog.com/28312626/the-basic-principles-of-fluoxetine